June 11, 2020
Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million
By Philippe Mendiharat
NEW YORK and SINGAPORE – June 11, 2020 – Travecta Therapeutics, a biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million. The fund-raise was led by TKS1, a life science focused venture capital fund formed by the partnership between SPRIM and Tikehau Capital.
“The positive traction we are having with our data along with the strength of interest from development and licensing partners has motivated our current investors to contribute an additional $12 million,” said Michael Shleifer, CEO of Travecta Therapeutics. “This financing will accelerate our trajectory into the next phase of development, and we’re thankful to our partners for the support.”
This funding comes on the heels of Travecta Therapeutics’ mVECTATM platform achieved targeting of a broad range of product candidates across the blood-brain-barrier with proven efficacy against pharmacological targets. “Our mVECTATM platform technology is unlocking key biological targets in neurological diseases that were previously difficult to engage because of the blood-brain barrier,” said Dr. Mahmood Ahmed, Chief Scientific Officer.
The proceeds from the Series A financing will be used to support Travecta’s growth and advance the development of TVT-004, Travecta’s lead non-opioid product targeting pain. The company plans to enter clinical trials in 2021. The funding will also support the progression of the company’s earlier stage research programs in neuro-oncology and neuro-inflammation.
Bruno de Pampelonne, Chairman of Tikehau IM said, “Travecta Therapeutics’ mVECTATM platform could revolutionize treatments in a broad range of neurological indications often very difficult to treat. We are thrilled to partner with Travecta’s team in this endeavor”
TRAVECTA’S MVECTATM PLATFORM
Travecta’s mVECTATM proprietary platform is built upon a deep understanding of the Mfs2da transporter protein and its function at the blood-brain-barrier as well as in other key physio-pathological conditions discovered by Dr. David Silver, Professor at Duke-NUS and Scientific Founder of Travecta.
ABOUT TRAVECTA THERAPEUTICS
Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier. The company’s proprietary platform mVECTATM allows to screen and develop product candidates that can cross the blood-brain barrier targeting novel and untapped neurological pathways.
Travecta Therapeutics was founded by Dr. David Silver and Dr. Mahmood Ahmed together with the SPRIM Ventures team.
For more information, visit: https://travectatherapeutics.com/.
Related Stories
SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy
NEW YORK – February 8, 2022 – SPRIM Global Investments announces the promotion of Susan Dallabrida, PhD, to Chief Executive Officer of SPRIM Consultancy. In her nearly 2 years with SPRIM, Susan has brought both scientific and commercial leadership to the business, boosting revenue while strengthening the company’s skill sets in clinical science and innovation. In…
Read More
BAC and Blade Announce Definitive Merger Agreement
Proposed merger to create publicly traded biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases….
Read More
AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies
SINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well as addressing the need to delay and overcome resistance to…
Read More
Leveraging Next-Gen Tools in Rare Disease Research
The capture of high-quality, accurate and complete datasets in a clinical trial is always of utmost importance. But the stakes could not be higher when it comes to rare disease. It is estimated that there are over 6,000 rare diseases globally. Of that, roughly 300 million people are currently affected with a rare disease today….
Read More
Fibronostics Raises $8 Million in Series A Financing
NEW YORK & SINGAPORE – August 24, 2020 – Fibronostics, a global company providing non-invasive, algorithmic diagnostics for NASH patients, announced today that it has secured $8 million in series A funding. The financing round was led by AT Capital, a leading private investment firm in Asia and Elev8.vc, an early-stage deep-tech VC fund. This funding…
Read More
The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training
The FDA recently released new guidance on drug development for the prevention and treatment of COVID-19, emphasizing the need for flexible trial designs, diverse patient populations and mechanisms to ensure data accuracy. Digital components that empower decentralized recruitment, e-consent, symptoms/adverse events monitoring, wearable data capture, and telehealth visits could provide researchers with a path forward to ensure…
Read More
ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients
PARIS — June 18, 2020 – ObvioHealth, a full-service virtual research organization (VROTM), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint Joseph. Participants will use Obvio-19, a proprietary mobile application and digital platform built by ObvioHealth,…
Read More
SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD
SPRIM and Health Catalyst partner to jumpstart understanding of COVID-19 impact on NASH and NAFLD population to advance clinical trials for liver disease. As the coronavirus pandemic continues to sweep across the globe, new concerns arise every day about the effect of COVID-19 on a patient’s long-term health. Among those emerging concerns is the association…
Read More
ObvioHealth Secures $17 Million in Latest Investment Round
SINGAPORE and NEW YORK – May 20, 2020 – ObvioHealth, a leading virtual health research organization or VROTM, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March. This milestone occurs at a critical time in…
Read More
Travecta Therapeutics Secures $15 Million in Financing
NEW YORK and SINGAPORE – May 12, 2020 – Travecta Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has secured US$15 million in its Series A round of financing, led by TKS1, a life science focused venture capital fund formed by the partnership between SPRIM and…
Read More